Chief Business Officer and Interim Chief Financial Officer · Black Diamond Therapeutics, Inc. (BDTX)

Fang Ni

A named executive officer of Black Diamond Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,489,526

Salary $450,865Stock awards $0

FY2022: $909,759

3rd of 4 named executive officers at Black Diamond Therapeutics by FY2023 total.

4 named officers on file for Black Diamond Therapeutics, FY2023

Fang Ni’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Black Diamond Therapeutics’s whole pay program stands against its peers

  • Black Diamond Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BDTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2024 (DEF 14A).

Free

Get Fang Ni’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Fang Ni compensation by year

Black Diamond Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Black Diamond Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$388,101$411,740$450,865
Bonus$25,000$0$0
Stock awards$0$0$0
Option awards$1,035,343$253,426$823,542
Non-equity incentive$131,955$196,977$189,361
Pension and deferred compensation$0$0$0
All other$94,171$47,616$25,758
Total$1,674,570$909,759$1,489,526

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Black Diamond Therapeutics, Inc. DEF 14A filed April 24, 2024, accession 0001104659-24-051211, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Black Diamond Therapeutics, Inc. filed document, accession 0001104659-24-051211. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2024.

$1.7M
$910K
$1.5M
FY21
FY22
FY23
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU19,000$53,390—
Option400,000—$2.92
Option20,002—$29.87
Option16,043—$28.69
Option54,167—$3.79

Per the Outstanding Equity Awards at Fiscal Year-End table in Black Diamond Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Black Diamond Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Mark VellecaPresident and Chief Executive Officer$2,949,854
David EpsteinFormer President and Chief Executive Officer$2,019,206
Fang Ni · this pageChief Business Officer and Interim Chief Financial Officer$1,489,526
Sergey YurasovChief Medical Officer$1,233,684

The full Black Diamond Therapeutics compensation record

free company brief

This page is one person within Black Diamond Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Black Diamond Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Fang Ni's compensation dossier · One-time report. No refunds.